^
    Back
    Association details:
    Biomarker:SIRT6 underexpression
    Cancer:Colon Cancer
    Drug:buparlisib (AN2025) (PI3K inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Theranostics
    Title:

    SIRT6, a novel direct transcriptional target of FoxO3a, mediates colon cancer therapy

    Published date:
    04/13/2019
    Excerpt:
    Knocking down SIRT6 abolished apoptotic responses and conferred resistance to the treatment of BKM120….The results uncover SIRT6 as a new potential biomarker for colon cancer, and its unappreciated mechanism about transcription and expression via Akt/FoxO3a pathway....Kaplan-Meier analysis showed that CRC patients with relative lower SIRT6 levels had shorter overall survival or disease-free survival times (Figure ​(Figure1F1F and G).
    DOI:
    10.7150/thno.29724